MaxCyte, Inc. Presentation at ICLE 2019
09 September 2019 - 4:01PM
RNS Non-Regulatory
TIDMMXCT
MaxCyte, Inc.
09 September 2019
MaxCyte Announces Presentation at ICLE 2019
Gaithersburg, Maryland - 9 September 2019 - MaxCyte (LSE: MXCT,
MXCS), the global cell-based therapies and life sciences company,
announces today that Director of Field Applications Scientists
Christopher Mann, PhD, will present on "Advancing Adoptive Cellular
Therapies Using Non-viral-based Engineering" at the 2nd
International Conference on Lymphocyte Engineering (ICLE 2019)
on Saturday 14 September at 9:50 a.m. BST.
The conference takes place 13-15 September 2019 at Novotel
London West Hotel, London, United Kingdom. For more information,
please visit: https://lymphocyte.kenes.com/
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company applying its proprietary cell engineering platform
to deliver the advances of cell-based medicine to patients with
high unmet medical needs. MaxCyte is developing novel CARMA
therapies for its own pipeline, with its first drug candidate in a
Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary
therapeutic platform for autologous cell therapy for the treatment
of solid cancers. In addition, through its life sciences business,
MaxCyte leverages its Flow Electroporation Technology to enable its
biopharmaceutical partners to advance the development of innovative
medicines, particularly in cell therapy. MaxCyte has placed its
flow electroporation instruments worldwide, including with all of
the top ten global biopharmaceutical companies. The Company now has
more than 80 partnered programme licenses in cell therapy with more
than 45 licensed for clinical use, including four announced
commercial licenses with aggregate potential milestones of more
than $250m. With its robust delivery technology platform, MaxCyte
helps its partners to unlock the full potential of their products.
For more information, visit www.maxcyte.com.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUGUQPBUPBPGR
(END) Dow Jones Newswires
September 09, 2019 02:01 ET (06:01 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024